Scarica l'app Stockscreener
46.11
1.56%
0.71
Dopo l'orario di chiusura:
46.11
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALKS Giù?
Forum
Previsione
Frazionamento azionario
Alkermes Plc Borsa (ALKS) Ultime notizie
Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program - Business Wire
After two decades at Alkermes, a biotech CFO joins Tortugas’ board - Stock Titan
Responsive Playbooks and the ALKS Inflection - Stock Traders Daily
Alkermes Plc (ALKS) Investor Outlook: Strong Buy Ratings And 21% Potential Upside - DirectorsTalk Interviews
Should Alkermes’ (ALKS) Narcolepsy Data And Phase 3 Pivot Reshape Investor Views On Its Pipeline? - simplywall.st
Alkermes (ALKS) EVP and CLO David Gaffin Sells 2,034 Shares - GuruFocus
Alkermes (NASDAQ: ALKS) officer readies stock sale - Stock Titan
Alkermes (NASDAQ: ALKS) exec lines up $423K stock sale - Stock Titan
ALKS News | ALKERMES PLC (NASDAQ:ALKS) - ChartMill
Mizuho reiterates Alkermes stock rating ahead of ADHD trial data By Investing.com - Investing.com South Africa
Mizuho reiterates Alkermes stock rating ahead of ADHD trial data - Investing.com
Alkermes plc (ALKS) Stock Analysis: Exploring an 18% Potential Upside with a Solid Revenue Growth Story - DirectorsTalk Interviews
Discipline and Rules-Based Execution in ALKS Response - Stock Traders Daily
Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000 - The Globe and Mail
Alkermes PLC (ALKS) Stock Down 3.1% but Still Overvalued -- GF S - GuruFocus
Rising Star: Goodwin's Heath Ingram - Law360
ALKS Looks 52.4% Overvalued on GF Value™ Amid New Drug Pricing D - GuruFocus
Alkermes narcolepsy drug shows positive phase 2 trial results By Investing.com - Investing.com Nigeria
The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1 - Yahoo Finance
Alkermes PLC (ALKS) Shares Fall 4.4% -- What GF Score of 64 Tells Investors - GuruFocus
Alkermes ends Amneal VIVITROL supply pact without penalties - scanx.trade
Alkermes reports phase 2 Vibrance-2 data; alixorexton meets dual primary endpoints in narcolepsy type 2 - scanx.trade
Alkermes (ALKS) Shares: Posts a 3.31% Loss to $48.52 for the Current Session; Current Setup: Traders Can Monitor the $46.09-$50.95 Range for the Current SessionStatistical Arbitrage - vinanet.vn
Q2 2026 Alkermes Plc Earnings Call Transcript - GuruFocus
Empowered Funds LLC Sells 53,381 Shares of Alkermes plc $ALKS - MarketBeat
STU:8AK EV-to-OCF: 37.38 — 44% Above Median - GuruFocus
Alkermes (ALKS) SVP, Chief Commercial Officer Christian Nichols Sells 7,576 Shares - GuruFocus
Alkermes (NASDAQ:ALKS) SVP Sells $372,966.48 in Stock - MarketBeat
Alkermes (NASDAQ: ALKS) holder to sell 7,576 shares worth $373K - Stock Titan
Alkermes (ALKS) Advances 1.53% as Shares Hold Firm Above Key SupportVOLD Alert - Vinanet
Alkermes Plc (ALKS) Stock Analysis: A Look At The 14.15% Potential Upside - DirectorsTalk Interviews
Alkermes (ALKS) Eases to $49.06: Key Levels to Watch After 0.79% DipPrice Target - Vinanet
S&CO Inc. Takes Position in Alkermes plc $ALKS - MarketBeat
Alkermes PLC (ALKS) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
ALKS Stock Surges 15% On Lilly-Centessa Buyout Igniting Sleep Pipeline Hopes - Stocktwits
Alkermes plc $ALKS Stock Position Trimmed by Empowered Funds LLC - MarketBeat
Quantinno Capital Management LP Grows Holdings in Alkermes plc $ALKS - MarketBeat
Bank of America Corp DE Trims Position in Alkermes plc $ALKS - MarketBeat
ALKS Stock Rises 27% in 3 Months: Here's What You Should Know - TradingView
Alkermes Lowers Interest Rate Spreads with Amendment to Credit Agreement - Kalkine Media
Alkermes amends credit agreement to reduce interest rates on term loans - Investing.com Nigeria
Form 8K Alkermes plc. For: 12 August By Investing.com - Investing.com Canada
Alkermes Reduces Spreads on $1.52 Billion Term Loans by Up to 75 bps - TradingView
Alkermes (NASDAQ: ALKS) lowers interest spreads on large term loan A and B debt - Stock Titan
Alkermes plc Enters into Amendment to Credit Agreement Reducing Interest Rate Spread on Term Loan Facilities - marketscreener.com
Hennion & Walsh Asset Management Inc. Makes New Investment in Alkermes plc $ALKS - MarketBeat
Could Alkermes plc (ALKS) Stock Rebound After Investors Look Beyond Near-Term Profit Pressure? - Yahoo Finance
Alkermes plc (ALKS) Stock Analysis: Evaluating a 13.89% Upside in the Biopharmaceutical Sector - DirectorsTalk Interviews
Alkermes Plc (ALKS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Did Alkermes’ (ALKS) Profit Slide and Cash-Conserving Moves Just Shift Its Investment Narrative? - simplywall.st
The Manufacturers Life Insurance Company Sells 42,319 Shares of Alkermes plc $ALKS - MarketBeat
Royal Bank of Canada Sells 21,159 Shares of Alkermes plc $ALKS - MarketBeat
(ALKS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Amundi Increases Stake in Alkermes plc $ALKS - MarketBeat
Alkermes plc $ALKS Shares Acquired by California State Teachers Retirement System - MarketBeat
Sei Investments Co. Has $5.44 Million Stake in Alkermes plc $ALKS - MarketBeat
Major Decision: Nancy Snyderman Exercises Options, Realizing $116K At Alkermes - Benzinga
Alkermes Insider Sold Shares Worth $2,239,076, According to a Recent SEC Filing - marketscreener.com
Form 4 Alkermes plc. For: 3 August By Investing.com - Investing.com South Africa
1.43%
0.92%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):